38 research outputs found

    Production of Y(1S) Mesons from chib Decays in pp(bar) Collisions at sqrt(s)=1.8 TeV

    Full text link
    We have reconstructed the radiative decays χb(1P)Υ(1S)γ\chi_{b}(1P) \to \Upsilon(1S) \gamma and χb(2P)Υ(1S)γ\chi_{b}(2P) \to \Upsilon(1S) \gamma in ppˉp \bar{p} collisions at s=1.8\sqrt{s} = 1.8 TeV, and measured the fraction of Υ(1S)\Upsilon(1S) mesons that originate from these decays. For Υ(1S)\Upsilon(1S) mesons with pTΥ>8.0p^{\Upsilon}_{T}>8.0 GeV/cc, the fractions that come from χb(1P)\chi_{b}(1P) and χb(2P)\chi_{b}(2P) decays are (27.1±6.9(stat)±4.4(sys))(27.1\pm6.9(stat)\pm4.4(sys))% and (10.5±4.4(stat)±1.4(sys))(10.5\pm4.4(stat)\pm1.4(sys))%, respectively. We have derived the fraction of directly produced Υ(1S)\Upsilon(1S) mesons to be (50.9±8.2(stat)±9.0(sys))(50.9\pm8.2(stat)\pm9.0(sys))%.Comment: 13 Pages, 2 figure

    Monoclonal antibody ONS-M21 recognizes integrin α3 in gliomas and medulloblastomas

    Get PDF
    The monoclonal antibody ONS-M21 recognizes an antigen found on the surface of glioma and medulloblastoma cells but does not react with the antigens of normal brain tissue. We purified and identified the 140-kDa protein by means of an antibody-binding affinity column. This 140-kDa antigen has sequences homologous to the amino-terminal region and five parts of the internal domain of integrin α3. When the integrin α3-related sequences was amplified and used to analyse the mRNA of glioma and medulloblastoma surgical specimens, the transcription level of integrin α3 mRNA appeared to be quantitatively correlated with the grade of malignancy. These findings suggest that the ONS-M21 antibody, which reacts with integrin α3, might be useful in the diagnosis of gliomas and medulloblastomas. © 1999 Cancer Research Campaig

    A comprehensive overview of radioguided surgery using gamma detection probe technology

    Get PDF
    The concept of radioguided surgery, which was first developed some 60 years ago, involves the use of a radiation detection probe system for the intraoperative detection of radionuclides. The use of gamma detection probe technology in radioguided surgery has tremendously expanded and has evolved into what is now considered an established discipline within the practice of surgery, revolutionizing the surgical management of many malignancies, including breast cancer, melanoma, and colorectal cancer, as well as the surgical management of parathyroid disease. The impact of radioguided surgery on the surgical management of cancer patients includes providing vital and real-time information to the surgeon regarding the location and extent of disease, as well as regarding the assessment of surgical resection margins. Additionally, it has allowed the surgeon to minimize the surgical invasiveness of many diagnostic and therapeutic procedures, while still maintaining maximum benefit to the cancer patient. In the current review, we have attempted to comprehensively evaluate the history, technical aspects, and clinical applications of radioguided surgery using gamma detection probe technology
    corecore